NCT05304130View on ClinicalTrials.gov

A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 8, 2023

Primary Completion Date

May 4, 2023

Study Completion Date

May 4, 2023

Conditions
Arthritis, Rheumatoid
Interventions
BIOLOGICAL

Otilimab

Otilimab will be administered via pre-filled syringe.

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT05304130 - A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab | Biotech Hunter | Biotech Hunter